Interruption of the Intratumor CD8:Treg Crosstalk Improves the Efficacy of PD-1 Immunotherapy

Shannon N Geels, Alexander Moshensky, Rachel S Sousa, Benjamin L. Walker, Rima Singh, Giselle Gutierrez, Ji Won Hwang, Thorsten R. Mempel, Qing Nie, Shivashankar Othy, Francesco MarangonibioRxiv 2023 · DOI

TL;DR

PD-1 blockade, a cornerstone of cancer immunotherapy, can paradoxically boost immunosuppressive T regulatory cells (Tregs), hindering treatment efficacy. This study reveals that activated CD8 T cells, not Tregs themselves, drive this Treg accumulation through IL-2 production, which upregulates ICOS on Tregs. Blocking this CD8-Treg crosstalk via ICOS inhibition before PD-1 therapy significantly improves anti-tumor responses, offering a novel strategy to enhance immunotherapy.

What Problem Does This Paper Address?

Cancer immunotherapy, particularly using PD-1 blockade, has revolutionized cancer treatment by unleashing the immune system's ability to fight tumors. However, a significant challenge is that many patients either don't respond or eventually relapse. One proposed reason for this resistance is the presence of tumor-infiltrating T regulatory cells (Tregs), which actively suppress anti-tumor immune responses. While inhibiting Tregs is a promising strategy, the precise mechanisms by which PD-1 blockade influences these immunosuppressive cells remain unclear. This paper aims to unravel how PD-1 blockade affects tumor Tregs and to identify a way to overcome this immunosuppressive effect to improve immunotherapy outcomes.

Methods

The researchers employed a multi-pronged approach:

  • Mouse Models: They used both immunogenic (D4M-S) and non-immunogenic (D4M) melanoma models in mice, along with MC38 colon carcinoma models.
  • Immunotherapy: They administered anti-PD-1 (αPD-1) antibodies, a standard immunotherapy.
  • Cell Depletion and Blocking: They used CD8-depleting antibodies and IL-2 neutralizing antibodies to investigate the roles of these components.
  • Intravital Microscopy (F-IVM): This advanced technique allowed real-time visualization of Treg behavior and calcium signaling within living tumors.
  • Genetic Manipulation: They used genetically modified mice to selectively delete PD-1 on Tregs or to track IL-2 production.
  • Flow Cytometry: This was used extensively to quantify cell populations, measure protein expression (e.g., Ki67, ICOS, GITR), and analyze cytokine production.
  • Meta-Analysis: They analyzed publicly available human patient data to see if their findings translated to humans.
  • CellChat Analysis: This computational tool was used to infer cell-cell communication pathways in human melanoma data.

Datasets

The study utilized:

  • Mouse Tumor Models: D4M, D4M-S (melanoma), and MC38 (colon carcinoma) cell lines.
  • Human Melanoma Datasets: Publicly available single-cell RNA sequencing data from Sade-Feldman et al. (2018) and bulk RNA sequencing data from Riaz et al. (2017), Gide et al. (2019), and Helmink et al. (2020).

Key Insights and Ideas

  • CD8 Cells are the Unexpected Drivers: The most surprising finding is that activated CD8 T cells, not Tregs themselves, are the primary drivers of Treg accumulation during PD-1 blockade. This challenges the assumption that PD-1 blockade directly impacts Tregs.
  • The IL-2/ICOS Axis is Crucial: CD8 T cells, upon activation by PD-1 blockade, produce IL-2. This IL-2 then acts on Tregs, upregulating the anti-apoptotic protein ICOS, which leads to their increased survival and accumulation.
  • Tumor Immunogenicity Matters: The effect of PD-1 blockade on Treg accumulation was significantly more pronounced in immunogenic tumors (like D4M-S) compared to non-immunogenic ones.
  • Interrupting the Crosstalk is Key: Blocking the interaction between CD8 cells and Tregs, specifically by inhibiting ICOS signaling, before initiating PD-1 therapy, dramatically improved tumor control in mice. This suggests a strategic window for intervention.
  • Human Relevance: The findings in mice were supported by meta-analysis of human melanoma patient data and computational analysis of human tumor transcriptomes, indicating that this CD8-Treg-IL-2-ICOS axis is relevant in human cancer.

Key Results

  • PD-1 blockade significantly increased the numbers of tumor Tregs in immunogenic melanoma models and in human melanoma patients.
  • This Treg increase was not due to cell-intrinsic PD-1 signaling in Tregs but rather an indirect effect mediated by CD8 T cells.
  • CD8 T cells, colocalized with Tregs in tumors, produced IL-2 after PD-1 blockade.
  • IL-2 upregulated ICOS on tumor Tregs, promoting their accumulation.
  • Inhibiting ICOS signaling before PD-1 immunotherapy led to increased control of immunogenic melanoma.
  • Meta-analysis of human melanoma patients showed a significant increase in tumor Tregs after PD-1 monotherapy.
  • CellChat analysis predicted an upregulated CD8/IL-2/Treg communication axis in human melanomas treated with PD-1 blockade.

Limitations and Future Work

  • Complexity of Treg Accumulation: While the CD8-IL-2-ICOS axis is a major contributor, the authors acknowledge that it might not be the sole mechanism responsible for Treg accumulation after PD-1 immunotherapy. Other factors could also play a role.
  • ICOSL Blockade Synergy: Concomitant blockade of ICOSL and PD-1 did not improve immunotherapy effectiveness, suggesting that ICOSL blockade also impacts effector T cells. However, sequential administration (ICOSL blockade first, then PD-1) showed significant synergy, highlighting the importance of timing.
  • Future Directions: The authors suggest that targeting the CD8-mediated, IL-2-dependent support to Tregs within the tumor microenvironment could be a promising strategy to enhance immunotherapy efficacy without causing widespread Treg depletion and autoimmunity. Further investigation into the precise timing and combination strategies for ICOSL and PD-1 blockade is warranted.

Summary updated

Abstract

SUMMARY PD-1 blockade unleashes the potent antitumor activity of CD8 cells but can also promote immunosuppressive T regulatory (Treg) cells, which may worsen response to immunotherapy. Tumor Treg inhibition is a promising strategy to overcome therapeutic resistance; however, the mechanisms supporting tumor Tregs during PD-1 immunotherapy are largely unexplored. Here, we report that PD-1 blockade increases tumor Tregs in mouse models of immunogenic tumors, including melanoma, and metastatic melanoma patients. Unexpectedly, Treg accumulation was not caused by Treg-intrinsic inhibition of PD-1 signaling but instead depended on an indirect effect of activated CD8 cells. CD8 cells colocalized with Tregs within tumors and produced IL-2, especially after PD-1 immunotherapy. IL-2 upregulated the anti-apoptotic protein ICOS on tumor Tregs, causing their accumulation. ICOS signaling inhibition before PD-1 immunotherapy resulted in increased control of immunogenic melanoma. Thus, interrupting the intratumor CD8:Treg crosstalk is a novel strategy that may enhance the efficacy of immunotherapy in patients.
BibTeX
@misc{geels2023interruption,
  author = {Shannon N Geels and Alexander Moshensky and Rachel S Sousa and Benjamin L. Walker and Rima Singh and Giselle Gutierrez and Ji Won Hwang and Thorsten R. Mempel and Qing Nie and Shivashankar Othy and Francesco Marangoni},
  title = {{Interruption of the Intratumor CD8:Treg Crosstalk Improves the Efficacy of PD-1 Immunotherapy}},
  year = {2023},
  doi = {10.1101/2023.05.15.540889},
  howpublished = {bioRxiv},
}
Figure